$MNMD as much as this has exploded I think it remains undervalued amongst its peers. $CMPS is at a 1.3-1.5 billion market cap, and its pipeline is - so far as I can see - one synthetic serotonin agonist for treatment resistant depression. Analysts have a 70$ PT for it YTD. Shifting to $MNMD, it has many trials, it has a rich pipeline and it is capped just under a billy. It is developing novel compounds, discovering their effects (in trials) and distributing them. From some pretty rudimentary math it’s value in a years time should be 260% greater than it is now. I’d be happy to know what you think :)
7
7
7 Likes